GH Research is a clinical-stage biopharmaceutical company developing mebufotenin-based therapies for treatment-resistant depression, bipolar II disorder, and postpartum depression. Their lead product, GH001, is a pulmonary inhalation formulation that aims to achieve rapid remission of depressive symptoms with a single dose, demonstrating a favorable tolerability profile and durable effects within a week.
Funding
Funding not disclosed
Founders
Product
Problem
Treatment-resistant depression, bipolar II disorder, and postpartum depression are difficult to treat, often requiring multiple interventions and extended periods to achieve remission. Existing treatments may have slow onset of action, limited durability, and significant side effects, creating a substantial burden for patients and healthcare providers.
Solution
GH Research is developing mebufotenin-based therapies, including GH001, a pulmonary inhalation formulation, designed for the rapid remission of depressive symptoms. GH001 aims to provide increased remission rates, faster onset of action, durable effects, and improved tolerability with a single-day administration. Early clinical data suggests that GH001 can induce remission of depressive symptoms within hours and maintain these effects for at least seven days, with a favorable tolerability profile.
Target Audience
The primary target audience includes individuals suffering from treatment-resistant depression, bipolar II disorder with a depressive episode, and postpartum depression, as well as the healthcare providers who treat these conditions.
Features
- Pulmonary inhalation formulation (GH001) for rapid absorption and onset of action
- Single-day dosing regimen to reduce treatment burden
- Mebufotenin-based therapies (GH001, GH002, GH003) with different routes of administration (inhalation, intravenous, nasal)
- Growing intellectual property portfolio covering novel uses, manufacturing methods, and aerosol compositions of mebufotenin
- Individualized dosing regimen (IDR) to optimize treatment response